Patents Examined by Rayna Rodriguez
-
Patent number: 11639483Abstract: Provided herein are uses of lactones, such as macrocyclic lactones, for use in consumer products.Type: GrantFiled: March 9, 2022Date of Patent: May 2, 2023Assignee: PHYTO TECH CORP.Inventors: Angélique Burke, Noemi Montoya, Katherine Joyce Oglesby
-
Patent number: 11591345Abstract: The present invention relates to crystalline polymorph forms of (S)-2-((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide (GDC-0077), having the structure, Formula I: or stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, and processes of preparing the polymorph forms.Type: GrantFiled: May 15, 2020Date of Patent: February 28, 2023Assignee: Genentech, Inc.Inventors: Paroma Chakravarty, Chong Han, Sean M. Kelly, Karthik Nagapudi, Scott Savage
-
Patent number: 11534446Abstract: It is provided a pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one, at least one sterol or an ester thereof and a mixture of acylglycerols with a solid fat content of less than 25% at 25° C. and 0% at 37° C. In addition it is provided a method for preparing the pharmaceutical composition.Type: GrantFiled: May 22, 2017Date of Patent: December 27, 2022Assignee: ASARINA PHARMA ABInventors: Torbjörn Bäckström, Anders Carlsson
-
Patent number: 11491136Abstract: Neuropeptide FF receptor modulators based on a proline scaffold are provided which offer NPFF receptor potencies in the nanomolar range and antagonistic selectivity for the NPFF1 receptor. Methods, compounds and compositions for modulating the function of neuropeptide FF receptors are provided for pharmacotherapies capable of influencing conditions or disorders affected by the neuropeptide FF receptors.Type: GrantFiled: February 13, 2018Date of Patent: November 8, 2022Assignee: RESEARCH TRIANGLE INSTITUTEInventors: Yanan Zhang, Thuy Nguyen
-
Patent number: 11491119Abstract: The present invention discloses a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids and its therapeutic application. More specifically, the present invention discloses the use of a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids in the therapeutic management of interstitial lung disease or lung fibrosis.Type: GrantFiled: October 15, 2020Date of Patent: November 8, 2022Assignee: SAMI-SABINSA GROUP LIMITEDInventors: Muhammed Majeed, Kalyanam Nagabhushanam, Lakshmi Mundkur, Rajendran Ramanujam
-
Patent number: 11471408Abstract: Provided herein are novel isotretinoin formulations that provide an enhanced targeted dermal delivery system for the drug isotretinoin with improved thermodynamic activity using no to a small level of ethanol relative to existing isotretinoin gel products, and methods for treatment of ichthyosis and other skin conditions using the same.Type: GrantFiled: May 15, 2020Date of Patent: October 18, 2022Assignee: TIMBER PHARMACEUTICALS LLCInventors: Zachary Rome, Charles Rodney Greenaway Evans, Marc Barry Brown, Francesco Caserta
-
Patent number: 11446281Abstract: The present invention relates to a composition for preventing, alleviating or treating inflammatory diseases, comprising, as an active ingredient, an acylhydrazone derivative compound, a stereoisomer thereof or a pharmaceutically acceptable salt thereof. an acylhydrazone derivative compound, a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of the present invention, effectively inhibits inflammatory cytokines and inflammatory signaling pathways, thereby effectively alleviating symptoms of inflammatory diseases such as dermatitis. Therefore, the composition according to the present invention may be effectively used for the prevention, alleviation or treatment of inflammatory diseases.Type: GrantFiled: January 11, 2019Date of Patent: September 20, 2022Assignee: Korea Research Institute Of Bioscience And BiotechnologyInventors: Bo Yeon Kim, Joonsung Hwang, Nak Kyun Soung, Jong Seog Ahn, Kyung Ho Lee, Jiyun Mun, Srinivasrao Ganipisetti, Hyunjoo Cha, Mija Ahn, Hee Gu Lee, Jae-Hyuk Jang, In Ja Ryoo, Sung-Kyun Ko
-
Patent number: 11433059Abstract: The present invention relates to a method of treating PIK3CA-Related Overgrowth Spectrum (PROS) more particularly, Congenital, Lipomatous, Overgrowth, Vascular Malformations, Epidermal Nevi and Spinal/Skeletal Anomalies and/or Scoliosis (CLOVES) 10 syndrome. To date, there are no specific treatments for patients and no animal models of PROS to better understand the physiopathology of the disorder. Inventors developed a genetic mouse model of PROS that recapitulates the human disease and demonstrated the efficacy of BYL719. Based on these results they treated two patients, one adult and one child, with severe CLOVES syndrome using BYL719. The drug had a robust efficiency on disease in the 15 two patients inducing quick recovery of all affected organs. Thus, the invention relates to a method of treating PROS in a subject in need thereof comprising the step of administrating the subject with a therapeutically effective amount of BYL719.Type: GrantFiled: February 17, 2017Date of Patent: September 6, 2022Inventor: Guillaume Canaud
-
Patent number: 11414410Abstract: The present invention is directed to methods of treating multiple myeloma by administering a compound of Formula (I) or pharmaceutically acceptable salt thereof.Type: GrantFiled: November 26, 2019Date of Patent: August 16, 2022Assignee: Alexion Pharmaceuticals, Inc.Inventors: Shawn M. Bauer, Zhaozhong J. Jia, Mukund Mehrotra, Yonghong Song, Qing Xu, Wolin Huang, Chandrasekar Venkataramani, Jack W. Rose, Anjali Pandey
-
Patent number: 11406638Abstract: The application refers to a novel combination treatment/combination medicament for PF-ILD treatment, comprising as a first combination partner a therapeutically effective amount of Nintedanib or a pharmaceutically acceptable salt thereof and as a second combination partner a therapeutically effective amount of a PDE4B-inhibitor of formula I wherein Ring A is a 6-membered aromatic ring which may optionally comprise one or two nitrogen atoms and wherein R is Cl and wherein R may be located either in the para-, meta- or ortho-position of Ring A, wherein S* is a sulphur atom that represents a chiral center or a pharmaceutically acceptable salt thereof. Hereby the second combination partner is preferably a therapeutically effective amount of the PDE4B-inhibitor of formula III or a pharmaceutically acceptable salt thereof.Type: GrantFiled: October 22, 2018Date of Patent: August 9, 2022Assignee: Boehringer Ingelheim Internatinal GmbHInventors: Franziska Elena Herrmann, Peter Nickolaus, Stefan Ludwig Michael Wollin
-
Patent number: 11389455Abstract: The disclosure generally relates to compounds, compositions, and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV-1 integrase, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.Type: GrantFiled: December 30, 2020Date of Patent: July 19, 2022Assignee: Institute for Cancer ResearchInventors: Mark D. Andrake, Anna Marie Skalka, George W. Merkel
-
Patent number: 11364214Abstract: Disclosed are compositions, methods of treatment using the compositions and methods of preparing the compositions for the treatment of eczema. The compositions may include propionic acid and/or non-steroidal esters of propionic acid. The compositions may further include a corticosteroid, immunomodulator, antibiotic, antibody, colloidal oatmeal, conditioned media prepared by bacterial fermentation, short chain fatty acids, picolinic acid, or emollient. The method of treatment may include analysis of the skin microbiome.Type: GrantFiled: May 18, 2017Date of Patent: June 21, 2022Assignee: Dermala, Inc.Inventors: Lada Rasochova, Michelle Kem
-
Patent number: 11285165Abstract: This invention provides novel polydentate selective high affinity ligands (SHALs) that can be used in a variety of applications in a manner analogous to the use of antibodies. SHALs typically comprise a multiplicity of ligands that each bind different region son the target molecule. The ligands are joined directly or through a linker thereby forming a polydentate moiety that typically binds the target molecule with high selectivity and avidity.Type: GrantFiled: April 8, 2020Date of Patent: March 29, 2022Assignees: Lawrence Livermore National Security, LLC, The Regents of the University of CaliforniaInventors: Sally J. DeNardo, Gerald L. DeNardo, Rodney L. Balhorn
-
Patent number: 11234956Abstract: The present invention provides pharmaceutical compositions comprising cannabinoids and N-acylethanolamines, and methods for their use in preventing and treating a variety of cannabinoid-treatable conditions.Type: GrantFiled: April 19, 2016Date of Patent: February 1, 2022Assignee: SciSparc Ltd.Inventors: Ascher Shmulewitz, Elran Haber, Ephraim Brener
-
Patent number: 11207290Abstract: The present invention provides pharmaceutical compositions comprising cannabinoids and N-acylethanolamines, and methods for their use in preventing and treating a variety of cannabinoid-treatable conditions.Type: GrantFiled: August 30, 2019Date of Patent: December 28, 2021Assignee: SciSparc Ltd.Inventors: Ephraim Brener, Elran Haber, Ascher Shmulewitz
-
Patent number: 11207331Abstract: Neuro-enhancing agents, compositions and methods are disclosed herein. Preferred neuro-enhancing agents of the present invention include progesterone and metabolites of progesterone, such as 3?-hydroxy-5?-pregnan-20-one (THP). These agents yield neuro-enhancing effects on neural cells that include neural progenitor and/or stem cells, whereby the agents stimulate mitosis of neural progenitor cells, stimulate neurite growth and organization, protect against neural loss, or one or more of these neural processes. Thus, the neuro-enhancing agents, compositions and methods disclosed herein are useful to reverse or prevent neurological disease or defects associated with neural loss or degeneration, such as Alzheimer's disease, neurological injuries, including injuries resulting from radiation therapy, and age-related neurological decline, including impairments in memory and learning.Type: GrantFiled: May 23, 2017Date of Patent: December 28, 2021Assignee: UNIVERSITY OF SOUTHERN CALIFORNIAInventors: Roberta Diaz Brinton, Jun Ming Wang
-
Patent number: 11197845Abstract: The present invention provides pharmaceutical compositions comprising cannabinoids and N-acylethanolamines, and methods for their use in preventing and treating a variety of cannabinoid-treatable conditions.Type: GrantFiled: October 10, 2019Date of Patent: December 14, 2021Assignee: SciSparc Ltd.Inventors: Ephraim Brener, Elran Haber, Ascher Shmulewitz
-
Patent number: 11192852Abstract: Disclosed herein are novel antioxidant inflammation modulators, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds and compositions thereof are also provided.Type: GrantFiled: December 3, 2019Date of Patent: December 7, 2021Assignee: REATA PHARMACEUTICALS, INC.Inventors: Eric Anderson, Gary L. Bolton, Bradley Caprathe, Xin Jiang, Chitase Lee, William H. Roark, Melean Visnick
-
Patent number: 11180460Abstract: The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.Type: GrantFiled: September 16, 2019Date of Patent: November 23, 2021Assignee: Novartis AGInventors: Daniela Angst, Francois Gessier, Anna Vulpetti
-
Patent number: 11147273Abstract: The present invention encompasses a stabilized parasiticidal granule composition comprising a macrocyclic lactone compound and an insect growth regulator. The invention also encompasses methods of making and methods of using the granule for treating, controlling or preventing parasitic infestation or parasitic infection in an animal.Type: GrantFiled: June 25, 2018Date of Patent: October 19, 2021Assignee: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.Inventors: Kour Chand Jindal, Jian Han, Kim Agnew